Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Chemistry

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1373/clinchem.2010.151472PMID 21610217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• External validation and head‐to‐head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets

  2009cited by this paper
• Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population

  2009cited by this paper
• New markers and multivariate models for prostate cancer detection.

  2009cited by this paper
• The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

  2008cited by this paper
• Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.

  2008cited by this paper
• A novel nomogram to predict the probability of prostate cancer on repeat biopsy.

  2008cited by this paper
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

  2008cited by this paper
• An artificial neural network for five different assay systems of prostate‐specific antigen in prostate cancer diagnostics

  2008cited by this paper
• Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards

  2008cited by this paper
• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring

  2008cited by this paper
• Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL

  2008cited by this paper
• PSA and other tissue kallikreins for prostate cancer detection.

  2007cited by this paper
• PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.

  2007cited by this paper
• Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction

  2007cited by this paper
• Assessing individual risk for prostate cancer.

  2007cited by this paper
• Prostate-specific antigen in clinical practice.

  2007cited by this paper
• Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.

  2007cited by this paper
• Development and external validation of an extended 10-core biopsy nomogram.

  2007cited by this paper
• A critical appraisal of logistic regression‐based nomograms, artificial neural networks, classification and regression‐tree models, look‐up tables and risk‐group stratification models for prostate cancer

  2007cited by this paper
• Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies

  2007cited by this paper
• Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

  2006cited by this paper
• Decision Curve Analysis: A Novel Method for Evaluating Prediction Models

  2006cited by this paper
• Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.

  2006cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen.

  2005cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

  2004cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level ⩽4.0 ng per milliliter

  2004cited by this paper
• Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening

  2004cited by this paper
• ROC curves in clinical chemistry: uses, misuses, and possible solutions.

  2004cited by this paper
• Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables.

  1999cited by this paper
• Evaluation of a Multivariate Prostate-Specific Antigen and Percentage of Free Prostate-Specific Antigen Logistic Regression Model in the Diagnosis of Prostate Cancer

  1999cited by this paper
• Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

  1998cited by this paper
• The clinical importance of free prostate-specific antigen (PSA).

  1998cited by this paper
• Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

  1991cited by this paper
• A concordance correlation coefficient to evaluate reproducibility.

  1989cited by this paper
• Prostate-Specific Antigen in Prostate Cancer

  1986cited by this paper
• Title: the Use of Prostate-specific Antigen in Prostate Cancer Diagnostics

  year unknowncited by this paper

• The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy

  2024cites this paper
• Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays

  2024influential citation
• Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice.

  2021cites this paper
• Internal Validation and Correlation of 2 Different Prostate Specific Antigen Assays for Prostate Cancer Screening in Community Based Men.

  2020cites this paper
• Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions.

  2020cites this paper
• Benefits and risks of standardization, harmonization and conformity to opinion in clinical laboratories

  2019cites this paper
• Differences in total PSA results within and between manufacturers.

  2018cites this paper
• Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer.

  2018cites this paper
• Clinical Utility of Gene Expression Cla...n With Newly Diagnosed Prostate Cancer

  2018cites this paper
• [Nomograms in routine clinical practice: Methodology, interest and limitations].

  2017cites this paper
• Metrological Traceability of Assays and Comparability of Patient Test Results.

  2017cites this paper
• Biomarker development, from bench to bedside

  2016cites this paper
• The Role of Complex PSA in the Prediction of Prostatic Cancer

  2015cites this paper
• Nomograms in oncology: more than meets the eye.

  2015cites this paper
• Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

  2015cites this paper
• Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods.

  2014cites this paper
• Metabolomics Approaches and Applications in Prostate Cancer Research

  2014cites this paper
• How to achieve harmonisation of laboratory testing -The complete picture.

  2014cites this paper
• Prostate specific antigen testing: age-related interpretation in early prostate cancer detection

  2013cites this paper
• Prostate cancer screening

  2012cites this paper
• An Appeal to Medical Journal Editors: The Need for a Full Description of Laboratory Methods and Specimen Handling in Clinical Study Reports

  2012cites this paper
• Implementation of standardization in clinical practice: not always an easy task

  2012cites this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports.

  2012cites this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Statement by the Consortium of Laboratory Medicine Journal Editors

  2012cites this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports

  2012cites this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports.

  2012cites this paper
• An appeal to medical journal editors: The need for a full description of laboratory methods and specimen handling in clinical study reports

  2012cites this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports

  2012cites this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports.

  2012cites this paper
• Description des méthodes de dosage et d’utilisation des échantillons dans les rapports d’études cliniques : traduction du rapport de consensus de l’ICMJE [DOI:10.1258/acb.2011.201201]

  2012cites this paper
• Patient safety and clinical effectiveness as imperatives for achieving harmonization inside and outside the clinical laboratory.

  2011cites this paper
• Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis.

  2011cites this paper
• Patient Safety and Clinical Effectiveness as Imperatives for Achieving Harmonization inside and outside the Clinical Laboratory

  2009cites this paper